Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S,R)-fidarestat
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
(S,R)-fidarestat is a stereoisomer of fidarestat, a small molecule inhibitor of aldose reductase. Aldose reductase is the first enzyme in the polyol pathway and plays a key role in the pathogenesis of diabetic complications by catalyzing the reduction of glucose to sorbitol. Inhibition of this enzyme reduces sorbitol accumulation in tissues and has been investigated as a therapeutic strategy for diabetic neuropathy. Fidarestat selectively binds to aldose reductase with high affinity and shows minimal off-target effects or direct pharmacological actions beyond AR inhibition. Clinical studies have shown that fidarestat can improve nerve conduction velocity and subjective symptoms associated with diabetic neuropathy without significant adverse effects or laboratory abnormalities[1][2][5]. The compound belongs to the hydantoin class of organic compounds.
- Other names
- (2S,4R)-2-aminoformyl-6-fluoro-spiro[chroman-4,4'-imidazolidine]-2',5'-dione(2S,4R)-6-fluoro-2',5'-dioxo-2,3-dihydrospiro[1-benzopyran-4,4'-imidazolidine]-2-carboxamide(S,R)-FIDARESTAT
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on (S,R)-fidarestat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (S,R)-fidarestat.